Rich66
01-17-2010, 12:37 PM
Yay! Focusing on fundamentals as opposed to limitless differences.
Basically suggesting pro-oxidation strategies with glycolysis inhibition may change things. Made me think about vitamin C (http://her2support.org/vbulletin/showthread.php?t=42028) + Metformin (http://her2support.org/vbulletin/showthread.php?t=39740). Maybe add some metronomic (http://her2support.org/vbulletin/showthread.php?t=42028)/chronomodulated chemo, targeted biologics, immune support, endocrine therapy and complementary supplementation..
http://www.molmed.org/content/papers%20in%20press/09_162_Lopez-Lazaro.pdf
Mol Med. 2010 Jan 9. [Epub ahead of print]
A new view of carcinogenesis and an alternative approach to cancer therapy.
López-Lázaro M (http://www.ncbi.nlm.nih.gov/pubmed?term=%22L%C3%B3pez-L%C3%A1zaro%20M%22[Author]&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_RVAbstract).
Department of Pharmacology, Faculty of Pharmacy, C/Profesor Garcia Gonzalez, 2, 41012, Sevilla, Spain.
Over the last few decades, cancer research has focused on the idea that cancer is caused by genetic alterations and that this disease can be treatable by reversing or targeting these alterations. The small variations in cancer mortality observed during the last 30 years indicate, however, that the clinical applications of this approach have been very limited so far. The development of future gene-based therapies that may have a major impact on cancer mortality may be compromised by the high number and variability of genetic alterations recently found in human tumors. This article reviews evidence that, in addition to acquiring a complex array of genetic changes, tumor cells develop an alteration in the metabolism of oxygen. Although both changes play an essential role in carcinogenesis, the altered oxygen metabolism of cancer cells is not subject to the high genetic variability of tumors and may therefore represent a more reliable target for cancer therapy. The utility of this novel approach for the development of therapies that selectively target tumor cells is discussed.
PMID: 20062820 [PubMed - as supplied by publisher]
Basically suggesting pro-oxidation strategies with glycolysis inhibition may change things. Made me think about vitamin C (http://her2support.org/vbulletin/showthread.php?t=42028) + Metformin (http://her2support.org/vbulletin/showthread.php?t=39740). Maybe add some metronomic (http://her2support.org/vbulletin/showthread.php?t=42028)/chronomodulated chemo, targeted biologics, immune support, endocrine therapy and complementary supplementation..
http://www.molmed.org/content/papers%20in%20press/09_162_Lopez-Lazaro.pdf
Mol Med. 2010 Jan 9. [Epub ahead of print]
A new view of carcinogenesis and an alternative approach to cancer therapy.
López-Lázaro M (http://www.ncbi.nlm.nih.gov/pubmed?term=%22L%C3%B3pez-L%C3%A1zaro%20M%22[Author]&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsP anel.Pubmed_RVAbstract).
Department of Pharmacology, Faculty of Pharmacy, C/Profesor Garcia Gonzalez, 2, 41012, Sevilla, Spain.
Over the last few decades, cancer research has focused on the idea that cancer is caused by genetic alterations and that this disease can be treatable by reversing or targeting these alterations. The small variations in cancer mortality observed during the last 30 years indicate, however, that the clinical applications of this approach have been very limited so far. The development of future gene-based therapies that may have a major impact on cancer mortality may be compromised by the high number and variability of genetic alterations recently found in human tumors. This article reviews evidence that, in addition to acquiring a complex array of genetic changes, tumor cells develop an alteration in the metabolism of oxygen. Although both changes play an essential role in carcinogenesis, the altered oxygen metabolism of cancer cells is not subject to the high genetic variability of tumors and may therefore represent a more reliable target for cancer therapy. The utility of this novel approach for the development of therapies that selectively target tumor cells is discussed.
PMID: 20062820 [PubMed - as supplied by publisher]